文章预览
Suzhou, June 5, 2024-Kintor
Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that its
in-house developed KX-826 has recently received the International Nomenclature
Cosmetic Ingredient (the “INCI”) review approval from the International
Cosmetic Ingredient Nomenclature Committee. The assigned INCI name is
Methylpyridinyl Fluoromethoxybenzonitrile Dimethyloxothiooxoimidazolidine. INCI names are systemic names recognized worldwide for the
identification of cosmetic ingredients and are cited by product labeling
regulations in many countries. The assignation would facilitate the global
launch of the Company's functional cosmetics with KX-826 as the main
ingredient. About Kintor Pharmaceutical Limited Founded
in 2009, Kintor Pharmaceutical Limited focuses on developing and
commercializing potential "first-in-class" and
"best-in-class" innovative drugs and functional cosmetics, aiming to
be a leading enterprise in such areas. After several years' development, the
Com
………………………………
